Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment
European Journal of Endocrinology · 2023
DOI: 10.1093/ejendo/lvac014 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Mai C Arlien-Søborg und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Acromegaly, Growth Hormone, Human Growth Hormone, Insulin Resistance. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: Independent Research Fund Denmark.
Abstract (Originalsprache)
Objectives
Insulin resistance is associated with ectopic lipid deposition. Growth hormone (GH) status also modulates ectopic lipid accumulation, but how this associates with insulin resistance in patients with GH disorders is not well established. Design and Methods Twenty-one patients diagnosed with acromegaly and 12 patients with adult GH deficiency (GHD) were studied at diagnosis and after treatment. A reference group of 12 subjects was included. Each study day comprised assessment of body composition with dual-energy X-ray absorptiometry, ectopic lipid deposition in the liver by MR spectroscopy, and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR).
Results
Disease control of acromegaly decreased lean body mass (LBM) (P < .000) and increased the percentage of total body fat (TBF) (P < .000). GH replacement increased LBM in the GHD patients (P = .007) and decreased the percentage of TBF (P = .010). The intrahepatic lipid (IHL) content increased after disease control in acromegaly (P = .004), whereas IHL did not change significantly after GH replacement in GHD (P = .34). Insulin resistance (HOMA-IR) improved after disease control of acromegaly (P < .000) and remained unaltered after GH replacement in the GHD patients (P = .829).
Conclusions
GH status is a significant modulator of body composition and insulin sensitivity. GH excess reduces total fat mass and intrahepatic lipid content together with induction of insulin resistance. The data support the notion that GH-induced insulin resistance is unassociated with hepatic lipid accumulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Medical Research Laboratory, Aarhus University Hospital, Aarhus, Denmark.
- Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, Denmark.
- Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark.
- Department of Pediatric and Adolescents Medicine, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, The MR Research Centre, Aarhus University Hospital, Aarhus, Denmark.
ORCID-Profile: Mai C Arlien-Søborg, Morten Høgild
Förderung
- Independent Research Fund Denmark
Zitieren
APA
Arlien-Søborg, M. C., Madsen, M. A., Dal, J., Krusenstjerna-Hafstrøm, T., Ringgaard, S., Skou, N., Høgild, M., & Jørgensen, J. O. L. (2023). Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvac014
Vancouver
Arlien-Søborg MC, Madsen MA, Dal J, Krusenstjerna-Hafstrøm T, Ringgaard S, Skou N, et al. Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvac014
BibTeX
@article{ArlienSborg2023,
author = {Arlien-Søborg, Mai C and Madsen, Michael Alle and Dal, Jakob and Krusenstjerna-Hafstrøm, Thomas and Ringgaard, Steffen and Skou, Nickolaj and Høgild, Morten and Jørgensen, Jens Otto Lunde},
title = {Ectopic lipid deposition and insulin resistance in patients with GH disorders before and after treatment},
journal = {European Journal of Endocrinology},
year = {2023},
doi = {10.1093/ejendo/lvac014}
}
EUVIMED